SCHEMBL5865115

SCHEMBL5865115

CCc1cc(N)cc(Br)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.45
NOS2 P35228 2/20 0.45
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
CHRM1 P11229 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
PDPK1 O15530 2/20 0.36
HRH3 Q9Y5N1 4/20 0.35
HTR6 P50406 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
HRH4 Q9H3N8 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7274937 0.84 NOS2 (0.54) NOS3NOS2GRIN2DGRIN3BCHRM1
SCHEMBL5865335 0.78 GRIN2D (0.39) GRIN2DGRIN3BCHRM1ADRA1DADRA1A
SCHEMBL10399435 0.77 NOS2 (0.65) NOS3NOS2GRIN2DGRIN3BCHRM1
SCHEMBL14595324 0.77 NOS3 (0.44) NOS3NOS2GRIN2DGRIN3BCHRM1
SCHEMBL3552503 0.76 NOS2 (0.52) NOS3NOS2GRIN2DGRIN3BCHRM1
SCHEMBL18611531 0.76 NOS2 (0.57) NOS3NOS2NOS1HEXAHEXB
SCHEMBL29739615 0.76 NOS2 (0.52) NOS3NOS2GRIN2DGRIN3BCHRM1
SCHEMBL221209 0.75
SCHEMBL26241408 0.74 NOS3 (0.45) NOS3NOS2GRIN2DGRIN3BCHRM1
SCHEMBL26241406 0.74 NOS3 (0.45) NOS3NOS2GRIN2DGRIN3BCHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100516061-C Pyridine derivatives as NMDA receptor ligands HOFFMANN LA ROCHE (CH) 2009-07-22 CN disclosed
CN-1837195-A Pyridine derivatives as nmda-receptor subtype blockers HOFFMANN LA ROCHE (CH) 2006-09-27 CN disclosed
US-7034044-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2006-04-25 US disclosed
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER 2006-03-16 US disclosed
EP-1448547-B1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2005-04-20 EP disclosed
CN-1585762-A Pyridine derivatives as NMDA receptor ligands HOFFMANN LA ROCHE (CH) 2005-02-23 CN disclosed
CN-1578662-A Pyridine derivatives as nmda-receptor subtype blockers HOFFMANN LA ROCHE (CH) 2005-02-09 CN disclosed
US-6831087-B2 2-(Pyrid-2- or 4-yl)-1,2,3,4-tetrahydroisoquinoline and derivatives; a good affinity to the NMDA receptor (N-methyl-D-asparate); acute/cronic neurodegenerative diseases; bacterial/viral infections; antidepressants; analgesics HOFFMANN-LA ROCHE INC. 2004-12-14 US disclosed
EP-1448547-A1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-25 EP disclosed
EP-1443926-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-11 EP disclosed
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER (FR) 2004-04-08 US disclosed
US-20030119870-A1 Pyridine substituted isoquinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-06-26 US disclosed
WO-2003040128-A1 PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-15 WO disclosed
WO-2003037333-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C NOS3 1666/4885NOS2 1824/4885GRIN2D 14/4885
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN3A, GRIN2C NOS3 1823/4885NOS2 2105/4885GRIN2D 15/4885
US-20030119870-A1 Pyridine substituted isoquinoline derivatives GRIN1, GRIN2C, GRIN2A NOS3 1727/4885NOS2 1336/4885GRIN2D 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.